Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-07-03 00:00:00 ET · period of report 2024-07-01 · accession 0001714899-24-000155 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-07-03 | 2024-07-01 | DNLI | SATO VICKI L | Dir | S - Sale | $22.14 | -3,080 | 119.4K | -3% | -$68.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-01 | S | D | 100 | $22.86 | 119,256 | D | — | — | (F3) Includes 5,967 unvested RSUs. |
| 2 | Common | Common Stock | 2024-07-01 | S | D | 2,980 | $22.12 | 119,356 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $21.86 to $22.83 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 5,967 unvested RSUs. |